Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against LENZ Therapeutics, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of LENZ Therapeutics, Inc. (“LENZ” or “the Company”) (NASDAQ: LENZ). Investors who purchased LENZ securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether LENZ has violated federal securities laws.
LENZ Investigation Details
On August 11, 2026, Lenz reported its second quarter 2026 financial results. While the Company reported total revenue of $5.5 million, the majority of this figure ($3.8 million) was driven by one-time, non-product global licensing milestones. Organic product sales for the Company’s primary commercial eye drop, VIZZ, came in flat at $1.73 million, representing just 9% volume growth quarter-over-quarter. The following day, August 12, 2026, Bank of America downgraded Lenz stock from “Buy” to “Neutral” and lowered its price target from $31.00 to $7.00, citing a significantly slower-than-expected commercial launch for VIZZ. Following this news, Lenz’s stock price fell sharply.
What’s Next for LENZ Investors?
If you are aware of any facts relating to this investigation or purchased LENZ securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
LENZ — Stock Performance
About Bronstein, Gewirtz & Grossman, LLC
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”